GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
NASDAQ:MIRN
Delisted

Mirna Therapeutics Fund Forecast

$1.71
+0 (+0%)
At Close: Sep 08, 2017
RSI low/high Values: [ 20 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

Mirna Therapeutics fund price down 0% on Friday
(Updated on Sep 08, 2017)

Sell candidate since Aug 28, 2017 PDF

No changes to the price of Mirna Therapeutics fund on the last trading day (Friday, 8th Sep 2017). During the last trading day the fund fluctuated 6.06% from a day low at $1.65 to a day high of $1.75. The price has been going up and down for this period, and there has been a 1.18% gain for the last 2 weeks.

The fund lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the fund is expected to rise 10.91% during the next 3 months and, with a 90% probability hold a price between $1.79 and $2.24 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

MIRN Signals & Forecast

The Mirna Therapeutics fund holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $1.71 and $1.70. A breakdown below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, September 07, 2017, and so far it has fallen 0%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Mirna Therapeutics fund

On the downside, the fund finds support just below today's level from accumulated volume at $1.53 and $1.51. There is a natural risk involved when a fund is testing a support level, since if this is broken, the fund then may fall to the next support level. In this case, Mirna Therapeutics finds support just below today's level at $1.53. If this is broken, then the next support from accumulated volume will be at $1.51 and $1.45.

In general the fund tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the fund During the last day, the fund moved $0.100 between high and low, or 6.06%. For the last week the fund has had daily average volatility of 6.06%

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (MIRN) For The Upcoming Trading Day Of Monday 11th

For the upcoming trading day on Monday, 11th we expect Mirna Therapeutics to open at $1.70, and during the day (based on 14 day Average True Range), to move between $1.61 and $1.81, which gives a possible trading interval of +/-$0.0994 (+/-5.81%) up or down from last closing price. If Mirna Therapeutics takes out the full calculated possible swing range there will be an estimated 11.63% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $1.71 (0.01%) than the support at $1.53 (10.53%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Mirna Therapeutics fund A Buy?

Mirna Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this fund.

Current score: -1.340 Sell Candidate Unchanged

Predicted Opening Price for Mirna Therapeutics of Monday, September 11, 2017

Fair opening price September 11, 2017 Current price
$1.70 ( 0.390%) $1.71

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for MIRN

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.80 5.46 %
R2 1.77 3.22 %
R1 1.74 1.84 %
Current price: 1.71
Support S1 1.67 -2.62 %
S2 1.64 -4.00 %
S3 1.60 -6.24 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 1.90 11.11 %
R2 1.74 1.75 %
R1 1.71 0.0058 %
Current price 1.71
Support S1 1.53 -10.53%
S2 1.51 -11.78%
S3 1.45 -15.20%

FAQ

What is the symbol for Mirna Therapeutics Fund and on which exchange is it traded?
The symbol for Mirna Therapeutics is MIRN and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Mirna Therapeutics Fund?
Mirna Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this fund.

How to buy Mirna Therapeutics Fund?
Mirna Therapeutics Fund can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Mirna Therapeutics Fund.

What's the current price of Mirna Therapeutics Fund?
As of the end of day on the 2017-09-08, the price of an Mirna Therapeutics (MIRN) share was $1.71.

What is the 52-week high and low for Mirna Therapeutics Fund?
The 52-week high for Mirna Therapeutics Fund is $2.58 and the 52-week low is $1.12.
Click to get the best stock tips daily for free!

About Mirna Therapeutics

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of microRNA-based oncology therapeutics. The company is developing mimics of naturally occurring microRNAs (miR) that are designed to restore tumor suppressor activity and aid appropriate anti-tumor immune response. Its lead product candidate is MRX34, a mimic of naturally occurring microRNA-34 encapsulated in a liposomal nanoparticle formulation which is in... MIRN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT